Candesartan versus imidapril in hypertension: A randomised study to assess effects of anti-AT1 receptor autoantibodies

Heart

Volumn 97, Issue 6, 2011, Pages 479-484

  Wei, Fen ^a   Jia, Xiu Jie ^b   Yu, Su Qin ^c   Gu, Ye ^c   Wang, Li ^d   Guo, Xiao Mei ^a   Wang, Min ^a   Zhu, Feng ^a   Cheng, Xiang ^a   Wei, Yu Miao ^a   Zhou, Zi Hua ^a   Fu, Micheal ^e   Liao, Yu Hua ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b CENTRAL CHINA NORMAL UNIVERSITY   (China)

^c Puai Hospital   (China)

^d First People's Hospital of Jiangxia District   (China)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTIBODY; AUTOANTIBODY; CANDESARTAN; CREATININE; IMIDAPRIL; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ABNORMAL LABORATORY RESULT; ADULT; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; COUGHING; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GINGIVA HYPERPLASIA; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA AND VOMITING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; AUTOANTIBODIES; BENZIMIDAZOLES; BLOOD PRESSURE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLIDINES; MALE; MIDDLE AGED; RECEPTOR, ANGIOTENSIN, TYPE 1; TETRAZOLES; TREATMENT OUTCOME;

EID: 79952003366     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2009.192104     Document Type: Article

References (13)

1. Dzielak DJ. The immune system and hypertension. Hypertension 1992;19(Suppl 1):I36-44.
2. Fu ML. Do immune system changes have a role in hypertension? J Hypertens 1995;13:1259-65.
3. Fu ML, Herlitz H, Wallukat G, et al. Functional autoimmune epitope on alpha-1 adrenergic receptor in patients with malignant hypertension. Lancet 1994;344:1660-3. (Pubitemid 24371095)
4. Fu ML, Herlitz H, Wallukat G, et al. Non-desensitized positive chronotropic effect of anti-angiotensin II receptor autoantibodies in patients with malignant hypertension [Abstract]. Circulation 1996;94:4046A.
5. Liao YH, Wei YM, Wang M, et al. Autoantibodies against AT1-receptor and alpha1-adrenergic receptor in patients with hypertension. Hypertens Res 2002;25:641-6.
6. Wallukat G, Homuth V, Fischer T, et al. Patients with preeclampsia develop agonistic antibodies against the angiotensin AT1 receptor. J Clin Invest 1999;1103:945-52. (Pubitemid 29169601)
7. Sun YX, Zhang HY, Wei YM, et al. The mechanism of signal transduction during vascular smooth muscle cell proliferation induced by autoantibodies against angiotensin AT1 receptor from hypertension. Chin Med J (Engl) 2008;121:43-8.
8. Wang B, Liao YH, Zhou ZH, et al. Arterial structure changes in rats immunized by AT1-receptor peptide. Heart Vessels 2005;20:153-8. (Pubitemid 41031013)
9. Liao YH, Wei YM, Wang M, et al. Pathogenesis and clinical intervention in refractory hypertensive patients: focus on the serum autoantibodies against AT1-receptors. Chin Med J Metallurg Ind 2001;18:65-9.
10. Fu ML, Leung PS, Wallukat G, et al. Agonist-like activity of antibodies to angiotensin II receptor subtype 1 (AT1) from rats immunized with AT1 receptor peptide. Blood Press 1999;8:317-24. (Pubitemid 30220296)
11. 2+ mobilization through angiotensin receptor activation. Circulation 2004;110:1612-19.
12. Dechend R, Homuth V, Wallukat G, et al. AT1 receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation 2000;101:2382-7. (Pubitemid 30329128)
13. Dechend R, Viedt C, Muller DN, et al. AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation 2003;107:1632-9. (Pubitemid 36401560)